New therapeutic targets identified in groundbreaking CRISPR study

Written by Jade Parker, Senior Editor

In one of the largest studies of its kind, researchers have performed genome-scale CRISPR–Cas9 screens to disrupt every gene in over 300 cancer models from 30 cancer types. From conducting the screens, the team from the Wellcome Sanger Institute (Cambridge, UK) and Open Targets discovered thousands of key genes essential for cancer cell growth.   Additionally, the researchers have developed a novel data-driven framework to prioritize and rank 600 drug targets that that hold the most promise for the development into cancer therapeutics.  “For the first time, in a data-driven way, we provide guidance at a genome-scale on which new therapeutic targets should be put forward for the development of new anti-cancer drugs,” commented co-first author Francesco Iorio, from...

To view this content, please register now for access

It's completely free